Properties of FDA-approved small molecule protein kinase inhibitors

Roskoski, Robert·2019·Pharmacological Research
DOI 10.1016/j.phrs.2019.03.006

Cites (225)

Items 201–225 of 225

  1. Erlotinib
    Martin B. Steins, Michael Thomas, Michael Geißler · 2018 · Recent results in cancer research/Recent Results in Cancer Research
  2. Cobimetinib Plus Vemurafenib: A Review in BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
    Gillian M. Keating · 2016 · Drugs
  3. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer
    Poupak Fallahi, Silvia Martina Ferrari, Enke Baldini, Marco Biricotti, Salvatore Ulisse, Gabriele Materazzi, Paolo Miccoli, Alessandro Antonelli · 2016 · Expert Review of Anticancer Therapy
  4. Progress in the problem of relapsed or refractory acute myeloid leukemia
    Alice S. Mims, William G. Blum · 2019 · Current Opinion in Hematology
  5. Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
    Rebecca Madden, Sam Kosari, Gregory Mark Peterson, Nasser Bagheri, Jackson Thomas · 2017 · International Journal of Clinical Pharmacology and Therapeutics
  6. Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy
    Paul William Manley, Giorgio Caravatti, Pascal Furet, Johannes L. Roesel, Phi Tran, Trixie Wagner, Markus Wartmann · 2018 · Biochemistry
  7. Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature
    Şeniz Öngören, Ahmet Emre Eşkazan, Veysel Suzan, Sercan Savcı, Işıl Erdoğan Özünal, Selin Berk, Fevzi Yalniz, Tuğrul Elverdi, Ayşe Salihoğlu, Yücel Erbilgin et al. · 2017 · Hematology
  8. Updates on managing advanced breast cancer with palbociclib combination therapy
    Teresa M. McShane, Thomas A. Wolfe, Joanne C Ryan · 2018 · Therapeutic Advances in Medical Oncology
  9. Emerging use of everolimus in the treatment of neuroendocrine tumors
    Pablo Gajate, Olga Martínez‐Sáez, Teresa Alonso‐Gordoa, Enrique Grande · 2017 · Cancer Management and Research
  10. Alectinib
    M. Herden, Cornelius Florian Waller · 2018 · Recent results in cancer research/Recent Results in Cancer Research
  11. Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods
    Sean Ekins, Nadia K. Litterman, Christopher A. Lipinski, Barry A. Bunin · 2015 · Pharmaceutical Research
  12. Bivalent Inhibitors of c-Src Tyrosine Kinase That Bind a Regulatory Domain
    Taylor K. Johnson, Matthew B. Soellner · 2016 · Bioconjugate Chemistry
  13. The role of abemaciclib in treatment of advanced breast cancer
    Amelia McCartney, Erica Moretti, Giuseppina Sanna, Marta Pestrin, Emanuela Risi, Luca Malorni, Laura Biganzoli, Angelo Di Leo · 2018 · Therapeutic Advances in Medical Oncology
  14. Irreversible Tyrosine Kinase Inhibition of Epidermal Growth Factor Receptor with Afatinib in Egfr Activating Mutation–Positive Advanced Non-Small-Cell Lung Cancer
    Sami Morin-Ben Abdallah, Vera Hirsh · 2018 · Current Oncology
  15. Palbociclib—The First of a New Class of Cell Cycle Inhibitors
    Marcus Schmidt, Martin Sebastian · 2018 · Recent results in cancer research/Recent Results in Cancer Research
  16. Glaucoma Drugs in the Pipeline
    Paul L. Kaufman, Mary Mohr, Scott P Riccomini, Carol A. Rasmussen · 2018 · Asia-Pacific Journal of Ophthalmology
  17. Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach
    Gheorghe D. Doros, Joseph M. Massaro, David E. Kandzari, Ron Waksman, Jacques Koolen, Donald E. Cutlip, Laura Mauri · 2017 · American Heart Journal
  18. A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma
    Hai-Tao Wang, Ming Xia · 2019 · Medicine
  19. Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis
    Tingyu Wen, Hai Tao Xiao, Chao Luo, Li Huang, Meimei Xiong · 2017 · Oncotarget
  20. Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer
    Ahmed Mohieldin, Ayman Ahamd Rasmy, Mohamed Ashour, Muath Al-Nassar, Rola H. Ali, Fahad G El-Enezi · 2018 · Cancer Management and Research
  21. Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents
    Roberto Iacovelli, Elena Verri, Maria Cossu Rocca, Gaetano Aurilio, Daniela Cullurà, Matteo Santoni, Ottavio DE COBELLI, Franco Nolè · 2016 · Critical Reviews in Oncology/Hematology
  22. Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib
    Tommaso Martino De Pas, Laura Pala, Chiara Catania, Fabio Conforti · 2017 · Future Oncology
  23. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation–Positive Acute Myeloid Leukemia
    Miryoung Kim, Sherry Williams · 2017 · Annals of Pharmacotherapy
  24. The Use of Alectinib in the First-Line Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
    Shirish M. Gadgeel · 2018 · Future Oncology
  25. Novel Approaches in Waldenström Macroglobulinemia
    Michael Alexander Spinner, Gaurav Varma, Ranjana H. Advani · 2018 · Hematology/Oncology Clinics of North America